E-paper
Authors list: Carraro, C; Bonaguro, L; Schulte-Schrepping, J; Horne, A, Oestreich, M; Warnat-Herresthal, S; Helbing, T; De Franco, M; Händler, K; Mukherjee, S; Ulas, T; Gandin, V; Göttlich, R; Aschenbrenner, AC; Schultze, JL; Gatto, B
Publication year: 2022
Journal: BioRxiv
DOI Link: https://doi.org/10.1101/2022.02.21.481294
Publisher: Cold Spring Harbor Laboratory
Omics-based technologies are driving major advances in precision medicine but efforts are still required to consolidate their use in drug discovery. In this work, we exemplify the use of multi-omics to support the development of 3-chloropiperidines (3-CePs), a new class of candidate anticancer agents. Combined analyses of transcriptome and chromatin accessibility elucidated the mechanisms underlying sensitivity to test agents. Further, we implemented a new versatile strategy for the integration of RNA-seq and ATAC-seq data, able to accelerate and extend the standalone analyses of distinct omic layers. This platform guided the construction of a perturbation-informed basal signature able to predict cancer cell lines’ sensitivity and to further direct compound development against specific tumor types. Overall, this approach offered a scalable pipeline to support the early phases of drug discovery, understanding of mechanism and potentially inform the positioning of therapeutics in the clinic.
Abstract:
Citation Styles
Harvard Citation style: Carraro, C., Bonaguro, L., Schulte-Schrepping, J., Horne, A., Warnat-Herresthal, S., Helbing, T., et al. (2022) Decoding mechanism of action and susceptibility to drug candidates from integrated transcriptome and chromatin state [Preprint]. BioRxiv, Article 2022.02.21.481294. https://doi.org/10.1101/2022.02.21.481294
APA Citation style: Carraro, C., Bonaguro, L., Schulte-Schrepping, J., Horne, A., Warnat-Herresthal, S., Helbing, T., De Franco, M., Händler, K., Mukherjee, S., Ulas, T., Gandin, V., Göttlich, R., Aschenbrenner, A., Schultze, J., & Gatto, B. (2022). Decoding mechanism of action and susceptibility to drug candidates from integrated transcriptome and chromatin state. BioRxiv. https://doi.org/10.1101/2022.02.21.481294